Sangmin Lee, MD, Weill Cornell Medicine, New York, NY, discusses hurdles in treating patients with acute myeloid leukemia (AML). Current treatments for AML include induction chemotherapy or venetoclax and hypomethylating agents, especially in older patients. Finding the optimal treatment for patients with AML who are 60-70 years old remains a challenge, and a personalized approach should be considered. Factors such as molecular risk and the use of targeted agents should be taken into account for such patients. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

свернуть